118 related articles for article (PubMed ID: 15948667)
1. Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.
Lee HS; Carmena M; Liskovykh M; Peat E; Kim JH; Oshimura M; Masumoto H; Teulade-Fichou MP; Pommier Y; Earnshaw WC; Larionov V; Kouprina N
Cancer Res; 2018 Nov; 78(21):6282-6296. PubMed ID: 30166419
[TBL] [Abstract][Full Text] [Related]
2. Telomerase and its potential for therapeutic intervention.
Phatak P; Burger AM
Br J Pharmacol; 2007 Dec; 152(7):1003-11. PubMed ID: 17603541
[TBL] [Abstract][Full Text] [Related]
3. Perifosine as a potential novel anti-telomerase therapy.
Holohan B; Hagiopian MM; Lai TP; Huang E; Friedman DR; Wright WE; Shay JW
Oncotarget; 2015 Sep; 6(26):21816-26. PubMed ID: 26307677
[TBL] [Abstract][Full Text] [Related]
4. Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity.
Zhu Z; Tran H; Mathahs MM; Fink BD; Albert JA; Moninger TO; Meier JL; Li M; Schmidt WN
Pharmacol Res Perspect; 2021 Dec; 9(6):e00882. PubMed ID: 34747573
[TBL] [Abstract][Full Text] [Related]
5. Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics.
Tao HY; Zhao CY; Wang Y; Sheng WJ; Zhen YS
Int J Nanomedicine; 2024; 19():3805-3825. PubMed ID: 38708177
[TBL] [Abstract][Full Text] [Related]
6. Telomerase: a nexus between cancer nanotherapy and circadian rhythm.
Ghosh PK; Rao MJ; Putta CL; Ray S; Rengan AK
Biomater Sci; 2024 Apr; 12(9):2259-2281. PubMed ID: 38596876
[TBL] [Abstract][Full Text] [Related]
7. Is telomerase a viable target in cancer?
Buseman CM; Wright WE; Shay JW
Mutat Res; 2012 Feb; 730(1-2):90-7. PubMed ID: 21802433
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic application of monoclonal antibodies in cancer: advances and challenges.
Modjtahedi H; Ali S; Essapen S
Br Med Bull; 2012; 104():41-59. PubMed ID: 23118261
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.
Buckley AF; Kakar S
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):305-9. PubMed ID: 17721276
[TBL] [Abstract][Full Text] [Related]
10. Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation.
Zohud BA; Guo P; Zohud BA; Li F; Hao JJ; Shan X; Yu W; Guo W; Qin Y; Cai X
Cell Death Dis; 2020 Oct; 11(10):879. PubMed ID: 33082305
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ionic Strength on Porphyrin Drugs Interaction with Quadruplex DNA Formed by the Promoter Region of C-myc and Bcl2 Oncogenes.
Nagesh N; Sharma VK; Ganesh Kumar A; Lewis EA
J Nucleic Acids; 2010; 2010():. PubMed ID: 20700417
[TBL] [Abstract][Full Text] [Related]
12. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.
Wangpaichitr M; Wu C; You M; Kuo MT; Feun L; Lampidis T; Savaraj N
Eur J Pharmacol; 2008 Sep; 591(1-3):124-7. PubMed ID: 18585380
[TBL] [Abstract][Full Text] [Related]
14. Telomerase: a potential therapeutic target for cancer.
Fletcher TM
Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
[TBL] [Abstract][Full Text] [Related]
15. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
16. Prospects for anti-neoplastic therapies based on telomere biology.
Stewart SA; Hahn WC
Curr Cancer Drug Targets; 2002 Mar; 2(1):1-17. PubMed ID: 12188917
[TBL] [Abstract][Full Text] [Related]
17. Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E
Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544
[TBL] [Abstract][Full Text] [Related]
18. The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches.
Salimi-Jeda A; Badrzadeh F; Esghaei M; Abdoli A
Cancer Treat Res Commun; 2021; 27():100323. PubMed ID: 33530025
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
